1. 201PEfficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial. (24th November 2019) Authors: Pang, J S-T; Shore, N; Smith, M R; Tammela, T L; Ulys, A; Vjaters, E; Polyakov, S; Jievaltas, M; Luz, M; Alekseev, B; Kuss, I; Le Berre, M-A; Snapir, A; Sarapohja, T; Fizazi, K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗